• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2015 Product Image

T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2015

  • ID: 1537341
  • June 2015
  • Region: Global
  • Bioseeker

Stimulation of the T cell receptor leads to the activation of NFkB and NFAT signaling modules which play a key role in T cell receptor signaling.
There are today 319 companies plus partners developing 404 T cell receptor pathway targeting drugs in 1601 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 201 drugs. T Cell Receptor Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 230 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 224 out of the 226 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 49 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update READ MORE >

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)